Business Context and Reporting Period
Company: IMMUCELL CORP (IMMUCELL CORPORATION)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2009
Business Overview: ImmuCell operates in a single segment focused on the development, acquisition, manufacture, and sale of products to improve the health and productivity of cows for the dairy and beef industries. Key products include First Defense® (a preventative vaccine for bovine enteritis) and Wipe Out® Dairy Wipes. The company is currently heavily investing in the internal development of Mast Out®, an intramammary infusion product for mastitis treatment.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenues | $2,462,834 | $2,461,925 |
| Net Loss | $(182,449) | $(160,124) |
| Net Loss Per Share (Basic & Diluted) | $(0.06) | $(0.06) |
| Cash and Cash Equivalents | $1,092,994 | $1,199,929 |
| Short-term Investments | $3,723,000 | $3,854,103 |
| Total Cash & Short-term Investments | $4,815,994 | $5,054,032 |
| Net Cash Used in Operating Activities | $(232,944) | $435,742 |
| Total Assets | $10,006,761 | $10,128,193 |
| Total Liabilities | $390,174 | $484,492 |
| Stockholders' Equity | $9,616,587 | $9,643,701 |
Debt and Liquidity: The company has no outstanding bank debt. Net working capital was approximately $6.19 million as of June 30, 2009. Management believes current capital resources are sufficient to fund operations for at least the next twelve months.
Material Changes vs. Prior Period
- Revenue: Total revenue remained virtually flat, increasing by less than 1% ($4,000) compared to the prior six-month period. Product sales increased slightly, but this was offset by a decrease in royalty income.
- Product Sales Mix: Sales of the lead product, First Defense®, decreased by 7% year-over-year for the six-month period. However, a backlog of approximately $287,000 in First Defense® orders existed at quarter-end, with 89% shipped in early July 2009.
- Expenses: Product development expenses increased by 22% ($166,000) to $921,439, primarily due to funding the development of Mast Out®. Conversely, product selling expenses decreased by 24% due to reduced advertising.
- Cash Flow: Operating cash flow turned negative, using $233,000 compared to providing $436,000 in the prior year, largely due to the timing of accounts receivable collections and increased inventory levels.
- Stockholder Equity: Equity decreased slightly due to the net loss, partially offset by proceeds from stock option exercises ($99,750).
Guidance, Outlook, and Risks
Outlook and Guidance:
- Management projects a net loss for the full year 2009, following a net loss in 2008, driven by the strategy to internally fund the development of Mast Out®.
- Sales are expected to be seasonal, with higher volumes in the first and fourth quarters.
- The company received a federal tax refund of approximately $361,000 in July 2009.
Management Commentary:
- Mast Out® Development: The pivotal effectiveness study for Mast Out® has completed the treatment phase. The company is awaiting data analysis and FDA approval for various technical sections (Environmental Impact, Target Animal Safety, Human Food Safety, CMC). A key competitive advantage sought is a "zero milk discard" claim.
- Economic Environment: The company notes significant economic pressure in the U.S. dairy industry, with milk prices plummeting 44% in the first half of 2009 compared to the prior year, forcing producers to cut costs.
Risks and Contingencies:
- Regulatory Approval: Commercialization of Mast Out® is contingent on FDA approval, which is not assured. European regulators are unlikely to approve a zero milk discard claim.
- Customer Concentration: Sales are heavily concentrated; two distributors accounted for 41% of sales in the first six months of 2009. Three distributors held 62% of trade accounts receivable.
- Market Conditions: The financial insecurity of the dairy industry poses a risk to sales volume and profitability.
- Stock Option Plan: The 2009 Stock Option and Incentive Plan was not approved by stockholders at the June 12, 2009 annual meeting.
Investor Verification Checklist
- Mast Out® Regulatory Status: Verify the timeline and results of the pivotal effectiveness study and the status of FDA technical section approvals, particularly regarding the "zero milk discard" claim.
- First Defense® Backlog: Confirm the realization of the $287,000 order backlog noted at June 30, 2009, and its impact on Q3 2009 revenue recognition.
- Dairy Industry Economics: Monitor Class III milk prices and the milk-feed price ratio to assess the financial health of the primary customer base.
- Customer Concentration: Review the stability of relationships with the top two distributors, which represent a significant portion of revenue and receivables.
- Cash Burn Rate: Track operating cash flow usage to ensure the $4.8 million in liquid assets remains sufficient to fund the projected 2009 net loss and ongoing development costs without dilution or debt.